Galapagos NV (GLPG) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 3 Phase 2[2], 1 Phase 1[3].
Trial NCT06652633[5] evaluates GLPG CAR T-cell therapy in Hematological Malignancies with a target enrollment of 546 participants.
No Form 4 insider filings for GLPG were recorded at the SEC in the past 30 days[6].